1007198-30-2

Upstream product

• 905752-33-2 2-t-butyldimethylsilyl-7-isopropoxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 25245-29-8 5-iodo-1,2,3-trimethoxybenzene 
• 905752-32-1 2-t-butyldimethylsilyl-3-formyl-6-methoxy-7-isopropoxybenzofuran 
• 905751-80-6 2-isopropoxy-3-methoxy-6-iodophenol 
• 945772-22-5 3-(t-butyldimethylsilyl)-1-(3,4,5-trimethoxyphenyl)propynone 

Downstream Products

• 905752-39-8 7-O-acyl-2-(t-butyldimethylsilyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 905752-37-6 2-(tert-butyldimethylsilyloxy)-7-acetoxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran 
• 905752-30-9 7-O-acyl-2-bromo-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 945828-45-5 dibenzyl 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate 
• 945771-74-4 2-methyl-7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan 
• 945771-78-8 2-cyano-7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan 

Relevant academic research and scientific papers

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[ b ]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

TREATMENT OF MACULAR DEGENERATION

The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds.

An efficient synthesis and substitution of 3-aroyl-2-bromobenzo[b]furans

(Chemical Equation Presented) A convenient method for the synthesis of 2-bromo-3-aroyl-benzo[b]furans from readily accessible precursors has been developed. The 2-bromo group has been employed as a versatile synthetic handle in both palladium-mediated cou

SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS

The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.

NOVEL TUBULIN POLYMERISATION INHIBITORS

The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds.